Matthew Osborne

C. E. Unterberg, Towbin is a global investment bank headquartered in New York City with additional offices in California and Israel. The firm provides investment banking, research and investment management services to emerging growth companies and investors in the technology, health care and defense, security and diversified technology sectors. C. E. Unterberg was founded in 1932 by Clarence Unterberg. In 1977, the firm merged with L. F. Rothschild to form L. F. Rothschild, Unterberg, Towbin. In 1990, the firm again became privately owned and independent when Clarence Unterberg's son, Thomas I. Unterberg, re-launched the firm as a full-service investment bank.

Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

FM Partners Holdings LLC is a broker/dealer headquartered in New York City. The firm was formerly known as Lazard Capital Markets LLC.. They are a subsidiary of LFCM Holdings LLC.

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA.

Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.